The  ||| S:0 E:4 ||| DT
effect  ||| S:4 E:11 ||| NN
of  ||| S:11 E:14 ||| IN
sildenafil  ||| S:14 E:25 ||| JJ
citrate  ||| S:25 E:33 ||| JJ
administration  ||| S:33 E:48 ||| NN
on  ||| S:48 E:51 ||| IN
selected  ||| S:51 E:60 ||| JJ
physiological  ||| S:60 E:74 ||| JJ
parameters  ||| S:74 E:85 ||| NNS
of  ||| S:85 E:88 ||| IN
exercising  ||| S:88 E:99 ||| VBG
Thoroughbred  ||| S:99 E:112 ||| JJ
horses  ||| S:112 E:119 ||| NNS
Sildenafil ||| S:119 E:129 ||| NNP
,  ||| S:129 E:131 ||| ,
a  ||| S:131 E:133 ||| DT
phosphodiesterase-5  ||| S:133 E:153 ||| FW
inhibitor  ||| S:153 E:163 ||| FW
vasodilator ||| S:163 E:174 ||| FW
,  ||| S:174 E:176 ||| ,
increases  ||| S:176 E:186 ||| VBZ
cGMP  ||| S:186 E:191 ||| JJ
concentrations  ||| S:191 E:206 ||| NNS
by  ||| S:206 E:209 ||| IN
inhibiting  ||| S:209 E:220 ||| JJ
enzymatic  ||| S:220 E:230 ||| JJ
degradation ||| S:230 E:241 ||| NN
.  ||| S:241 E:243 ||| .
Marketed  ||| S:243 E:252 ||| VBN
to  ||| S:252 E:255 ||| TO
treat  ||| S:255 E:261 ||| VB
erectile  ||| S:261 E:270 ||| JJ
dysfunction  ||| S:270 E:282 ||| NN
in  ||| S:282 E:285 ||| IN
men ||| S:285 E:288 ||| NNS
,  ||| S:288 E:290 ||| ,
it  ||| S:290 E:293 ||| PRP
also  ||| S:293 E:298 ||| RB
reduces  ||| S:298 E:306 ||| VBZ
pulmonary  ||| S:306 E:316 ||| JJ
arterial  ||| S:316 E:325 ||| JJ
pressure  ||| S:325 E:334 ||| NN
( ||| S:334 E:335 ||| -LRB-
PAP ||| S:335 E:338 ||| NNP
) ||| S:338 E:339 ||| -RRB-
.  ||| S:339 E:341 ||| .
Because  ||| S:341 E:349 ||| IN
it  ||| S:349 E:352 ||| PRP
reduces  ||| S:352 E:360 ||| VBZ
PAP ||| S:360 E:363 ||| NNP
,  ||| S:363 E:365 ||| ,
sildenafil  ||| S:365 E:376 ||| NNS
may  ||| S:376 E:380 ||| MD
enhance  ||| S:380 E:388 ||| VB
performance  ||| S:388 E:400 ||| NN
and ||| S:400 E:403 ||| CC
/ ||| S:403 E:404 ||| NNP
or  ||| S:404 E:407 ||| CC
prevent  ||| S:407 E:415 ||| VB
exercise  ||| S:415 E:424 ||| VB
induced-pulmonary  ||| S:424 E:442 ||| JJ
haemorrhage  ||| S:442 E:454 ||| NNS
( ||| S:454 E:455 ||| -LRB-
EIPH ||| S:455 E:459 ||| NNP
) ||| S:459 E:460 ||| -RRB-
.  ||| S:460 E:462 ||| .
To  ||| S:462 E:465 ||| TO
determine  ||| S:465 E:475 ||| VB
if  ||| S:475 E:478 ||| IN
sildenafil  ||| S:478 E:489 ||| JJ
citrate  ||| S:489 E:497 ||| JJ
administration  ||| S:497 E:512 ||| NN
altered  ||| S:512 E:520 ||| VBD
commonly  ||| S:520 E:529 ||| RB
measured  ||| S:529 E:538 ||| VBN
indices  ||| S:538 E:546 ||| NNS
of  ||| S:546 E:549 ||| IN
performance  ||| S:549 E:561 ||| NN
or  ||| S:561 E:564 ||| CC
reduced  ||| S:564 E:572 ||| VBD
EIPH  ||| S:572 E:577 ||| NNP
in  ||| S:577 E:580 ||| IN
exercised  ||| S:580 E:590 ||| JJ
horses ||| S:590 E:596 ||| NNS
.  ||| S:596 E:598 ||| .
Thirteen  ||| S:598 E:607 ||| FW
athletically  ||| S:607 E:620 ||| FW
conditioned  ||| S:620 E:632 ||| FW
Thoroughbred  ||| S:632 E:645 ||| FW
horses  ||| S:645 E:652 ||| FW
( ||| S:652 E:653 ||| -LRB-
2  ||| S:653 E:655 ||| CD
mares  ||| S:655 E:661 ||| NNS
and  ||| S:661 E:665 ||| CC
11  ||| S:665 E:668 ||| CD
geldings ||| S:668 E:676 ||| NN
,  ||| S:676 E:678 ||| ,
age  ||| S:678 E:682 ||| NN
3-12  ||| S:682 E:687 ||| CD
years ||| S:687 E:692 ||| NNS
)  ||| S:692 E:694 ||| -RRB-
were  ||| S:694 E:699 ||| VBD
administered  ||| S:699 E:712 ||| VBN
sildenafil  ||| S:712 E:723 ||| JJ
citrate  ||| S:723 E:731 ||| NN
or  ||| S:731 E:734 ||| CC
placebo  ||| S:734 E:742 ||| NN
in  ||| S:742 E:745 ||| IN
2  ||| S:745 E:747 ||| CD
crossover  ||| S:747 E:757 ||| JJ
design  ||| S:757 E:764 ||| NN
exercise  ||| S:764 E:773 ||| NN
testing  ||| S:773 E:781 ||| NN
studies ||| S:781 E:788 ||| NNS
.  ||| S:788 E:790 ||| .
In  ||| S:790 E:793 ||| IN
a  ||| S:793 E:795 ||| DT
step-wise  ||| S:795 E:805 ||| JJ
test  ||| S:805 E:810 ||| NN
to  ||| S:810 E:813 ||| TO
exhaustion ||| S:813 E:823 ||| VB
,  ||| S:823 E:825 ||| ,
inspired ||| S:825 E:833 ||| VBD
/ ||| S:833 E:834 ||| NNP
expired  ||| S:834 E:842 ||| VBD
gas  ||| S:842 E:846 ||| NN
analysis ||| S:846 E:854 ||| NN
,  ||| S:854 E:856 ||| ,
blood  ||| S:856 E:862 ||| NN
lactate ||| S:862 E:869 ||| NN
,  ||| S:869 E:871 ||| ,
heart  ||| S:871 E:877 ||| NN
rate ||| S:877 E:881 ||| NN
,  ||| S:881 E:883 ||| ,
runtime  ||| S:883 E:891 ||| NN
and  ||| S:891 E:895 ||| CC
bronchoalveolar  ||| S:895 E:911 ||| JJ
lavage  ||| S:911 E:918 ||| NNS
( ||| S:918 E:919 ||| -LRB-
BAL ||| S:919 E:922 ||| NNP
)  ||| S:922 E:924 ||| -RRB-
cytology  ||| S:924 E:933 ||| NN
were  ||| S:933 E:938 ||| VBD
measured ||| S:938 E:946 ||| VBN
.  ||| S:946 E:948 ||| .
In  ||| S:948 E:951 ||| IN
a  ||| S:951 E:953 ||| DT
13  ||| S:953 E:956 ||| CD
m ||| S:956 E:957 ||| CD
/ ||| S:957 E:958 ||| CD
s  ||| S:958 E:960 ||| JJ
test  ||| S:960 E:965 ||| NN
to  ||| S:965 E:968 ||| TO
exhaustion ||| S:968 E:978 ||| VB
,  ||| S:978 E:980 ||| ,
blood  ||| S:980 E:986 ||| NN
lactate ||| S:986 E:993 ||| NN
,  ||| S:993 E:995 ||| ,
heart  ||| S:995 E:1001 ||| NN
rate ||| S:1001 E:1005 ||| NN
,  ||| S:1005 E:1007 ||| ,
runtime ||| S:1007 E:1014 ||| NN
,  ||| S:1014 E:1016 ||| ,
BAL  ||| S:1016 E:1020 ||| NNP
cytology  ||| S:1020 E:1029 ||| NN
and  ||| S:1029 E:1033 ||| CC
pulmonary  ||| S:1033 E:1043 ||| JJ
arterial  ||| S:1043 E:1052 ||| JJ
pressure  ||| S:1052 E:1061 ||| NN
were  ||| S:1061 E:1066 ||| VBD
measured ||| S:1066 E:1074 ||| VBN
.  ||| S:1074 E:1076 ||| .
Data  ||| S:1076 E:1081 ||| NNP
were  ||| S:1081 E:1086 ||| VBD
analysed  ||| S:1086 E:1095 ||| VBN
with  ||| S:1095 E:1100 ||| IN
paired  ||| S:1100 E:1107 ||| NN
and  ||| S:1107 E:1111 ||| CC
unpaired  ||| S:1111 E:1120 ||| JJ
t  ||| S:1120 E:1122 ||| JJ
tests ||| S:1122 E:1127 ||| NNS
,  ||| S:1127 E:1129 ||| ,
one-way  ||| S:1129 E:1137 ||| JJ
ANOVA  ||| S:1137 E:1143 ||| NNP
and  ||| S:1143 E:1147 ||| CC
Tukey ||| S:1147 E:1152 ||| NNP
's  ||| S:1152 E:1155 ||| POS
pair-wise  ||| S:1155 E:1165 ||| JJ
multiple  ||| S:1165 E:1174 ||| JJ
comparison  ||| S:1174 E:1185 ||| NN
and  ||| S:1185 E:1189 ||| CC
Friedman  ||| S:1189 E:1198 ||| NNP
repeated  ||| S:1198 E:1207 ||| VBD
measure  ||| S:1207 E:1215 ||| NN
analysis  ||| S:1215 E:1224 ||| NN
of  ||| S:1224 E:1227 ||| IN
variance  ||| S:1227 E:1236 ||| NN
on  ||| S:1236 E:1239 ||| IN
ranks ||| S:1239 E:1244 ||| NNS
.  ||| S:1244 E:1246 ||| .
The  ||| S:1246 E:1250 ||| DT
administration  ||| S:1250 E:1265 ||| NN
of  ||| S:1265 E:1268 ||| IN
sildenafil  ||| S:1268 E:1279 ||| NN
did  ||| S:1279 E:1283 ||| VBD
not  ||| S:1283 E:1287 ||| RB
alter  ||| S:1287 E:1293 ||| VB
mean  ||| S:1293 E:1298 ||| VB
inspired ||| S:1298 E:1306 ||| VBN
/ ||| S:1306 E:1307 ||| NNP
expired  ||| S:1307 E:1315 ||| VBD
gas  ||| S:1315 E:1319 ||| NN
measurements ||| S:1319 E:1331 ||| NNS
,  ||| S:1331 E:1333 ||| ,
plasma  ||| S:1333 E:1340 ||| JJ
lactate  ||| S:1340 E:1348 ||| JJ
concentrations  ||| S:1348 E:1363 ||| NNS
or  ||| S:1363 E:1366 ||| CC
acute  ||| S:1366 E:1372 ||| JJ
pulmonary  ||| S:1372 E:1382 ||| JJ
haemorrhage  ||| S:1382 E:1394 ||| NN
in  ||| S:1394 E:1397 ||| IN
either  ||| S:1397 E:1404 ||| DT
exercise  ||| S:1404 E:1413 ||| NN
test  ||| S:1413 E:1418 ||| NN
or  ||| S:1418 E:1421 ||| CC
pulmonary  ||| S:1421 E:1431 ||| JJ
arterial  ||| S:1431 E:1440 ||| JJ
pressure  ||| S:1440 E:1449 ||| NN
measurement  ||| S:1449 E:1461 ||| NN
in  ||| S:1461 E:1464 ||| IN
the  ||| S:1464 E:1468 ||| DT
13  ||| S:1468 E:1471 ||| CD
m ||| S:1471 E:1472 ||| CD
/ ||| S:1472 E:1473 ||| CD
s  ||| S:1473 E:1475 ||| JJ
trial ||| S:1475 E:1480 ||| NN
.  ||| S:1480 E:1482 ||| .
Heart  ||| S:1482 E:1488 ||| NN
rates  ||| S:1488 E:1494 ||| NNS
in  ||| S:1494 E:1497 ||| IN
both  ||| S:1497 E:1502 ||| DT
stress  ||| S:1502 E:1509 ||| NN
tests  ||| S:1509 E:1515 ||| NNS
were  ||| S:1515 E:1520 ||| VBD
significantly  ||| S:1520 E:1534 ||| RB
different  ||| S:1534 E:1544 ||| JJ
at  ||| S:1544 E:1547 ||| IN
submaximal  ||| S:1547 E:1558 ||| JJ
speeds  ||| S:1558 E:1565 ||| NNS
and  ||| S:1565 E:1569 ||| CC
during  ||| S:1569 E:1576 ||| IN
the  ||| S:1576 E:1580 ||| DT
early  ||| S:1580 E:1586 ||| JJ
recovery  ||| S:1586 E:1595 ||| NN
period ||| S:1595 E:1601 ||| NN
.  ||| S:1601 E:1603 ||| .
Run  ||| S:1603 E:1607 ||| NN
time  ||| S:1607 E:1612 ||| NN
was  ||| S:1612 E:1616 ||| VBD
not  ||| S:1616 E:1620 ||| RB
affected  ||| S:1620 E:1629 ||| VBN
by  ||| S:1629 E:1632 ||| IN
sildenafil  ||| S:1632 E:1643 ||| JJ
administration  ||| S:1643 E:1658 ||| NN
in  ||| S:1658 E:1661 ||| IN
the  ||| S:1661 E:1665 ||| DT
step-wise  ||| S:1665 E:1675 ||| JJ
trial  ||| S:1675 E:1681 ||| NN
( ||| S:1681 E:1682 ||| -LRB-
P  ||| S:1682 E:1684 ||| NN
=  ||| S:1684 E:1686 ||| SYM
0.622 ||| S:1686 E:1691 ||| CD
)  ||| S:1691 E:1693 ||| -RRB-
or  ||| S:1693 E:1696 ||| CC
in  ||| S:1696 E:1699 ||| IN
the  ||| S:1699 E:1703 ||| DT
13  ||| S:1703 E:1706 ||| CD
m ||| S:1706 E:1707 ||| CD
/ ||| S:1707 E:1708 ||| CD
s  ||| S:1708 E:1710 ||| JJ
trial  ||| S:1710 E:1716 ||| NN
( ||| S:1716 E:1717 ||| -LRB-
P  ||| S:1717 E:1719 ||| NN
=  ||| S:1719 E:1721 ||| SYM
0.059 ||| S:1721 E:1726 ||| CD
) ||| S:1726 E:1727 ||| -RRB-
.  ||| S:1727 E:1729 ||| .
Sildenafil  ||| S:1729 E:1740 ||| NNP
did  ||| S:1740 E:1744 ||| VBD
not  ||| S:1744 E:1748 ||| RB
alleviate  ||| S:1748 E:1758 ||| VB
pulmonary  ||| S:1758 E:1768 ||| JJ
haemorrhage  ||| S:1768 E:1780 ||| NN
or  ||| S:1780 E:1783 ||| CC
enhance  ||| S:1783 E:1791 ||| VB
performance-related  ||| S:1791 E:1811 ||| JJ
indices  ||| S:1811 E:1819 ||| NNS
in  ||| S:1819 E:1822 ||| IN
these  ||| S:1822 E:1828 ||| DT
trials ||| S:1828 E:1834 ||| NNS
.  ||| S:1834 E:1836 ||| .
Sildenafil  ||| S:1836 E:1847 ||| JJ
administration  ||| S:1847 E:1862 ||| NN
altered  ||| S:1862 E:1870 ||| VBD
cardiovascular  ||| S:1870 E:1885 ||| JJ
adaptation  ||| S:1885 E:1896 ||| NN
to  ||| S:1896 E:1899 ||| TO
intense  ||| S:1899 E:1907 ||| JJ
exercise  ||| S:1907 E:1916 ||| NN
as  ||| S:1916 E:1919 ||| IN
evidenced  ||| S:1919 E:1929 ||| VBN
by  ||| S:1929 E:1932 ||| IN
altered  ||| S:1932 E:1940 ||| JJ
heart  ||| S:1940 E:1946 ||| NN
rates  ||| S:1946 E:1952 ||| NNS
at  ||| S:1952 E:1955 ||| IN
submaximal  ||| S:1955 E:1966 ||| JJ
speeds  ||| S:1966 E:1973 ||| NNS
and  ||| S:1973 E:1977 ||| CC
post  ||| S:1977 E:1982 ||| NN
exercise ||| S:1982 E:1990 ||| NN
.  ||| S:1990 E:1992 ||| .
The  ||| S:1992 E:1996 ||| DT
effect  ||| S:1996 E:2003 ||| NN
of  ||| S:2003 E:2006 ||| IN
these  ||| S:2006 E:2012 ||| DT
alterations  ||| S:2012 E:2024 ||| NN
on  ||| S:2024 E:2027 ||| IN
other  ||| S:2027 E:2033 ||| JJ
performance  ||| S:2033 E:2045 ||| NN
perimeters  ||| S:2045 E:2056 ||| NNS
was  ||| S:2056 E:2060 ||| VBD
not  ||| S:2060 E:2064 ||| RB
evident ||| S:2064 E:2071 ||| JJ
.  ||| S:2071 E:2073 ||| .
